Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other ...

This approval makes Ozempic the first GLP-1 treatment for patients with both conditions. Chronic kidney disease is common in people with diabetes. About one in three adults with diabetes have kidney ...

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. About one in six people in San Antonio have type 2 diabetes, and a third ...

10% less likely to need hospital care and 36% less apt to see their kidney disease progress compared to patients taking a DPP4i drug, the study found. Advertisement "People with diabetes and ...

Researchers enrolled 10,584 patients with chronic kidney disease, type 2 diabetes, and additional cardiovascular risk factors; randomly assigned them to sotagliflozin or placebo; and followed them ...

as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD), the Danish drugmaker said on Tuesday. Novo's blockbuster diabetes drug Ozempic belongs to a class of ...